Registration Form

The following journal publication is being provided as a professional courtesy by
Novartis Pharmaceuticals Corporation. entitled "Secukinumab is Superior to Ustekinumab in Clearing Skin of Subjects with Moderate-to-Severe Plaque Psoriasis up to 1 Year: Results From The CLEAR Study".
To view file please fill out required information and click Continue button.

As you know, the Sunshine Act requires that manufacturers of pharmaceuticals must collect and track data regarding payments and other transfers of value that they provide to physicians and teaching hospitals. These data must be electronically submitted to CMS annually.

Please complete the form below in compliance with the Sunshine Act reporting requirements. This reprint has a value of $7.09. Over the course of a year, transfers of value less than $10 do not require reporting by Novartis, except when the total annual value of payments or other transfers of value provided to you by Novartis exceeds $100.

Please select a Healthcare Provider Type to begin.
* Required fields













(ex. ME Number, NPI Number etc.)


 


 

Accessing reprint
Once you have registered, you will be able to access reprint.
Click on the Continue button to access file.

6/17 COS-1344009-C
We respect your privacy. For more information, please view our privacy policy.
Contact us with questions or comments.